Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Spinal biologics can alter the existing biological environment to enhance specific cellular/molecular activity to further a clinical goal by facilitating osteoinduction, osteoconduction, and/or osteogenesis.
Autograft can be taken from the iliac crest or locally from the spinous processes and lamina; its trabecular surface area serves as a scaffold and allows vascular/cellular ingrowth. Autograft contains growth factors such as bone morphogenetic proteins, insulin growth factors, and fibroblast growth factors and also delivers both mesenchymal and primary cells that lead to bone regeneration and remodeling.
Advantages of allograft are access to a large supply of bone, avoidance of an iliac crest bone graft harvest procedure, and cost-effectiveness compared with other substitutes such as recombinant bone morphogenetic protein–2.
Although the osteoinductive properties of demineralized bone matrices are variable, it can serve as a reasonable bone graft extender when used in combination with autograft.
Ceramic-based bone grafts serve as an osteoconductive scaffold for bone growth and allow for adequate spinal fusion without the problems associated with obtaining adequate autograft or the potential risks of allograft.
Mesenchymal stem cells are pluripotent cells that can be isolated from adipose tissue, bone marrow, and muscle tissue and can be induced to become osteoprogenitor cells.
Recombinant human bone morphogenetic protein–2 (rhBMP-2) is a growth factor of the transforming growth factor family that initiates a biochemical pathway that leads to increased expression of genes, which potentiates mesenchymal stem cells into osteogenic differentiation. Its success in achieving spinal fusion has led to widespread applications in all areas of the spine. There are significant risks with the use of rhBMP-2 in the anterior cervical spine, so it should not be used there. Being aware of potential complications that can occur with rhBMP-2 allows the surgeon to rapidly identify and appropriately treat them.
Although there are several indications and various techniques used for spine fusion surgery, the fundamental aim is to augment or restore spinal stability by achieving solid bony union between two or more vertebral motion segments. Regardless of the clinical setting, successful achievement of an arthrodesis can be a major predictor of outcome. For example, in the treatment of lumbar degenerative spondylolisthesis, improvements in patient outcomes are seen throughout the fusion process and are maintained after confirmed fusion. In patients with thoracolumbar spinal deformity, successful fusion leads to significantly higher quality-of-life outcome scores relative to those with a pseudarthrosis. Finally, in the cervical spine, patients who achieve a solid fusion after anterior cervical discectomy and fusion (ACDF) experience significantly greater improvements in pain and disability outcomes relative to those who fail to fuse. Augmentation with biologics is one strategy aimed at increasing the rate of successful fusion.
From a biological perspective, spinal fusion is challenging because the goal is to achieve bone growth in an environment not originally developed for this purpose (i.e., the disc space, intertransverse space), which necessitates modification of the biological microenvironment to stimulate and support the process. Biologics can enhance specific cellular and molecular activity, which helps to accomplish arthrodesis by facilitating osteoinduction, osteoconduction, or osteogenesis. Bone healing is a cellular process that requires critical thresholds of bone-forming osteoblasts, osteoprogenitor cells, local vascular tissues, and the cells involved in the inflammatory response. The osteogenic potential of a graft material refers to its ability to directly provide the local fusion bed with these primary osteoblasts or responding cells. Osteoinduction describes the stimulation of cellular events that transform previously uncommitted stem cells into those that will form new bone. Osteoinductive stimuli may also facilitate angiogenesis or vascular ingrowth to supply the fusion site with the cells, growth factors, and nutrients required for fusion. Osteoconduction is the local environmental support of these cells and enhancement of their functions. An osteoconductive material acts as a scaffold that permits the migration, attachment, differentiation, and proliferation of osteogenic cells and the other cells contributing to the bone healing response, facilitating subsequent bone and vascular ingrowth. This chapter identifies and critically evaluates the available biological agents used in spine surgery to facilitate bone fusion.
Care to preserve the local blood supply is important because, in addition to providing essential nutrients to the healing tissue, it can be a potential source of osteoprogenitor cells. Preparation of the host bone surface is key because the local bone can be an excellent source of osteogenic cells and osteoinductive signals, while also providing an osteoconductive surface for new bone growth.
Finally, the location of fusion is a major factor that must be considered. Boden emphasized this at the time that he first characterized the biology of fusion in the lumbar spine, making it clear that the results of healing for a grafting material in one region of the spine should not necessarily be extrapolated to other regions. This is because the fusion environment differs substantially in different locations throughout the spine. For example, the interbody fusion environment includes a large bony surface area providing a wide cancellous bed for graft contact, excellent vascularity of well-exposed end plates, and compression loading of graft material, all of which enhance the potential for fusion. The posterior intertransverse fusion environment is much more challenging owing to the limited surface area for healing, the large defect size between transverse processes which must be bridged, the lack of external support in fixating graft materials, and the influence of tensile forces.
Historically, the most commonly used spinal biologic is autograft. Autologous bone grafts are the only graft materials possessing all three essential properties of osteogenesis, osteoinduction, and osteoconduction. Further advantages include low cost and absent risk of disease transmission. There are two main types of autograft. These include local bone graft harvested from laminectomy and/or facetectomy sites, and extraspinal material harvested from the iliac crest.
Iliac crest bone graft (ICBG) consists of (cortico) cancellous bone that provides an excellent environment for rapid new bone formation and remains the biologic that most completely satisfies the three essential criteria. It provides an osteoconductive matrix of collagen, mineral, and matrix proteins that contains osteogenic bone and marrow cells lining the surface of trabeculae, plus ample endogenous osteoinductive growth factors. Advantages include high arthrodesis rates and the ability to harvest large amounts of bone. For these reasons, ICBG is the gold standard for spinal fusion, against which all other biological options are compared.
Despite the excellent fusion rates, the use of ICBG is limited by a number of well-documented disadvantages related to the graft harvest. These include increased blood loss, operative time, and length of hospital stay, , as well as the potential for a number of perioperative complications. Among these, postoperative donor-site pain is a commonly reported issue, , which can be activity-limiting and can persist in the long term. , Other less common donor-site complications include postoperative infection and hematoma. Although uncommon, there also exists a potential for catastrophic complications, including superior gluteal artery injury and spinopelvic dissociation.
Several surgical techniques have been explored as a means of reducing the morbidity associated with ICBG harvest, , including minimally invasive harvesting methods and even iliac crest defect reconstruction. However, a single, optimal method of obtaining ICBG has not been definitively established. One intervention that has proven effective at reducing the rate of donor-site pain after ICBG harvest is the perioperative administration of local anesthetics. Singh and colleagues demonstrated that the use of an indwelling catheter with continuous infusion of 0.5% Marcaine at the ICBG site for 48 hours after surgery resulted in a significant reduction in pain scores in both the immediate postoperative period and at long-term follow-up. Similar reductions in short- and long-term pain scores are achieved with a single administration of bupivacaine at the ICBG harvest site. ,
Despite numerous reports of harvest-site pain and significant efforts aimed at reducing its impact, there is ongoing debate about the true incidence of this complication. Sheha and associates recently performed a prospective, randomized cohort study in which patients undergoing one- to two-level elective spinal fusion between L4 and S1 for spinal stenosis and spondylolisthesis were randomized to left-sided or right-sided ICBG donor sites and blinded to the laterality of the harvest. They found pain on the operative side to be slightly higher, but it was not statistically or clinically significantly different from pain reported at the nonoperative site at any time point throughout the study. A similar study was performed by Lehr and colleagues. They found that patients could not reliably identify the iliac crest that was used for harvest, and that the operative side was not more painful than the nonoperative side.
In conclusion, ICBG remains an effective option for achieving high rates of bony fusion in all areas of the spine, but significant harvest-related morbidity has led to a search for alternatives.
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here